



**Figure 1**

*Radioligand binding results ( $IC_{50}$  values)  
for certain compounds of the present invention*




**3**  
 $IC_{50}$  values  
 $D_{2L}$  (human) < 500 nM  
 $D_{4.4}$  (human) > 1  $\mu$ M  
 $5HT_{1A}$  (human) < 500 nM  
 $5HT_{2A}$  (human) < 100 nM  
 $5HT_{2B}$  (human) < 100 nM  
 $5HT_{2C}$  (human) < 100 nM  
 $\alpha_{1A}$  (rat) < 100 nM  
 $\alpha_{1D}$  (human) < 100 nM  
 $\alpha_{2A}$  (human) < 1  $\mu$ M



**4**  
 $IC_{50}$  values  
 $D_{2L}$  (human) < 500 nM  
 $5HT_{2A}$  (human) < 100 nM  
 $5HT_{2B}$  (human) < 10 nM  
 $5HT_{2C}$  (human) < 500 nM

**Figure 2**

*Radioligand binding results ( $IC_{50}$  values)  
for certain compounds of the present invention*



**5**


$IC_{50}$  values

$D_{2L}$  (human) < 5  $\mu$ M

5HT<sub>2A</sub> (human) < 10 nM

5HT<sub>2B</sub> (human) < 10 nM

5HT<sub>2C</sub> (human) < 10 nM



**6**

$IC_{50}$  values

$D_{2L}$  (human) < 5  $\mu$ M


5HT<sub>2A</sub> (human) < 10 nM

5HT<sub>2B</sub> (human) < 100 nM

5HT<sub>2C</sub> (human) < 10 nM

**Figure 3**

*Radioligand binding results ( $IC_{50}$  values)  
for certain compounds of the present invention*



**7**

$IC_{50}$  values

$D_{2L}$  (human) > 1  $\mu$ M

$D_3$  (human) < 1  $\mu$ M

5HT<sub>1</sub> (rat) > 1  $\mu$ M


5HT<sub>1A</sub> (human) < 500 nM

5HT<sub>2</sub> (rat) < 100 nM

5HT<sub>2A</sub> (human) < 10 nM

5HT<sub>2B</sub> (human) < 100 nM

5HT<sub>2C</sub> (human) < 100 nM



**8**

$IC_{50}$  values

$D_{2L}$  (human) < 1  $\mu$ M

$D_3$  (human) < 1  $\mu$ M

5HT<sub>1</sub> (rat) > 1  $\mu$ M

5HT<sub>1A</sub> (human) < 1  $\mu$ M

5HT<sub>2</sub> (rat) < 100 nM


5HT<sub>2A</sub> (human) < 10 nM

5HT<sub>2B</sub> (human) < 100 nM

5HT<sub>2C</sub> (human) < 10 nM

**Figure 4**

*Radioligand binding results ( $IC_{50}$  values)  
for certain compounds of the present invention*



**9**

$IC_{50}$  values

$D_{2L}$  (human) < 1  $\mu$ M

$D_3$  (human) < 500 nM

$D_{4.4}$  (human) > 1  $\mu$ M

5HT<sub>1A</sub> (human) < 500 nM

5HT<sub>2A</sub> (human) < 500 nM

5HT<sub>2B</sub> (human) < 100 nM


5HT<sub>2C</sub> (human) < 500 nM

5HT<sub>6</sub> (human) > 1  $\mu$ M

$\alpha_{1A}$  (rat) < 1  $\mu$ M

$\alpha_{1D}$  (human) > 1  $\mu$ M

$\alpha_{2A}$  (human) > 1  $\mu$ M



**11**

$IC_{50}$  values

$D_{2L}$  (human) < 1  $\mu$ M

$D_{2S}$  (human) < 1  $\mu$ M

$D_3$  (human) < 1  $\mu$ M

$D_{4.4}$  (human) > 1  $\mu$ M

5HT<sub>2</sub> (rat) > 1  $\mu$ M


5HT<sub>3</sub> (human) > 1  $\mu$ M

5HT<sub>6</sub> (human) > 1  $\mu$ M

5HT<sub>7</sub> (human) < 1  $\mu$ M

**Figure 5**

*Radioligand binding results ( $IC_{50}$  values)  
for certain compounds of the present invention*



**13**

$IC_{50}$  values

$D_{2L}$  (human) < 500 nM

$5HT_{2A}$  (human) < 100 nM


$5HT_{2B}$  (human) < 100 nM

$5HT_{2C}$  (human) < 500 nM

$\alpha_{1A}$  (rat) > 1  $\mu$ M

$\alpha_{1D}$  (human) < 500 nM

$\alpha_{2A}$  (human) < 1  $\mu$ M



**14**

$IC_{50}$  values

$D_{2L}$  (human) < 500 nM

$5HT_{2A}$  (human) < 500 nM

$5HT_{2B}$  (human) < 100 nM

$5HT_{2C}$  (human) < 500 nM


$\alpha_{1A}$  (rat) < 100 nM

$\alpha_{1D}$  (human) < 100 nM

$\alpha_{2A}$  (human) < 1  $\mu$ M

**Figure 6**

*Radioligand binding results ( $IC_{50}$  values)  
for certain compounds of the present invention*



**15**

$IC_{50}$  values

NE Transporter (human) <500 nM


D<sub>2L</sub> (human) <500 nM

D<sub>3</sub> (human) <500 nM

DA Transporter (human) <100 nM

5-HT<sub>7</sub> (human) <500 nM

5-HT Transporter (human) >1  $\mu$ M



**16**

$IC_{50}$  values

alpha 1 (rat) <1  $\mu$ M

alpha 2 (rat) <1  $\mu$ M

D<sub>2L</sub> (human) <1  $\mu$ M

D<sub>2S</sub> (human) >1  $\mu$ M

D<sub>3</sub> (human) <1  $\mu$ M

D<sub>4.4</sub> (human) >1  $\mu$ M

5-HT<sub>7</sub> (human) <1  $\mu$ M

5-HT<sub>2A</sub> (human) <1  $\mu$ M